Dr. Nejat F. Eczacıbaşı completed his studies in 1942, returned home, and established the foundation of Turkey's first modern pharmaceutical production facility, Eczacıbaşı Pharmaceutical Industry in 1952. The company lead Turkish pharmaceutical industry with its high standards and innovations.
To benefit from the changes in Turkey, Eczacıbaşı Pharmaceutical Industry started to seek strategic partners within the global pharmaceutical market, in 2007, it transferred 75 per cent of their shares in Eczacıbaşı Sağlık Ürünleri and Eczacıbaşı Özgün Kimya to Zentiva N.V., one of Europe's leading companies in the field of equivalent pharmacy field. The transfer of the remaining 25 percent partnership took place in July 2009.
The title of Eczacıbaşı Pharmaceutical Industry has changed and the new title ''Eczacıbaşı Pharmaceutical and Industrial Investment Co'' was published in Turkish Trade Registry Gazette on 24 November 2008, No. 7195 edition. Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar, which does not have production activities, has a kind of holding structure with its existing subsidiaries, business partnerships and affiliates. Within this structure, it directly engages in real estate development activities and acts as a strategic partner in healthcare, building products and other industries.
EIS was established on October 24th, 1951.
ECILC
EIS went public in 1990.
The shares of EİS are traded on Borsa İstanbul A.Ş.
According to Central Registry Agency Inc. records; as of 31 December 2022, it is accepted that the shares representing 18.76% of the company's capital are "in circulation".
According to Central Registry Agency Inc. records; as of 31 March 2023, it is accepted that the shares representing 18,74% of the company's capital are "in circulation".
| Trade Title | Share Ratio (%) | |
|---|---|---|
| Gensenta İlaç Sanayi ve Ticaret A.Ş. | 99,96 | |
| EİP Eczacıbaşı İlaç Pazarlama A.Ş. | 99,92 | |
| Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım A.Ş. | 99,49 | |
| Eczacıbaşı İlaç Ticaret A.Ş. | 94,70 | |
| Eczacıbaşı Monrol Nükleer Ürünler Sanayi ve Ticaret A.Ş. | 57,50 | |
| Eczacıbaşı Holding A.Ş. | 37,28 | |
| Ekom Eczacıbaşı Dış Ticaret A.Ş. | 26,36 | |
| Vitra Karo Sanayi ve Ticaret A.Ş. | 25,00 | |
| Eczacıbaşı Bilişim Sanayi ve Ticaret A.Ş. | 11,21 | |
| Sector/Market of Activity | Corporate Name | |
| Healthcare Sector (*) | ||
| Reference and generic pharmaceuticals market | Gensenta İlaç Sanayi ve Ticaret A.Ş. | |
| EİP Eczacıbaşı İlaç Pazarlama A.Ş. | ||
| Eczacıbaşı İlaç Ticaret A.Ş. | ||
| Nuclear medicine sector | Eczacıbaşı Monrol Nükleer Ürünler Sanayi ve Ticaret A.Ş. | |
| Monrol Europe SRL | ||
| Monrol Egypt for Manufacturing LLC (**) | ||
| Radiopharma Egypt (S.A.E) | ||
| Monrol Bulgaria LTD | ||
| Eczacıbaşı Monrol Nuclear Products Industry&Trade Co-Jordan (***) | ||
| Monrol MENA LTD | ||
| Monrol Gulf DMCC | ||
| HSM Consulting LTD | ||
| Monrol GMBH | ||
| Real Estate Activities | Kanyon (*) | |
| Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım A.Ş. | ||
| Other | ||
| Seramik kaplama pazarı | Vitra Karo Sanayi ve Ticaret A.Ş. | |
| Dışsatım hizmetleri | Ekom Eczacıbaşı Dış Ticaret A.Ş. | |
(*) This means the entire Kanyon Office Block and the half of the Shopping Mall.
(**) The company is in liquidation.
(***) The company does not have any activity.
Information on the activities of subsidiaries, affiliates and business partnerships are included in the annual reports that are prepared quarterly and annually. Click here to reach the annual reports of EIS.
Click here to reach the articles of association of EIS.
Click here for shareholding structure of EIS.
EIS’ issued capital is TL 685,260,000.
Click here for information about the capital movements of EIS.
The number of shares representing the issued capital of EIS is 68,526,000.000. There is no privileged share and each share has one voting right.
The Board of Directors of the company consists of 6 members and 2 of the members are independent members. Click here to reach information about the board of directors.
The fiscal year of EIS starts on January 1 and ends on December 31.
EİS discloses its consolidated financial results quarterly. Click here to reach the quarterly financial reports.
The Ordinary General Assembly Meeting of EIS for 2021 was held on Thursday, April 11, 2023. Click here for information on the 2023 Ordinary General Assembly Meeting.
Click here to reach the profit distribution policy of EIS.
Click here to reach the profit distribution details of EIS.
At the Ordinary General Assembly Meeting of EIS dated 11.04.2023, it has been resolved that, in compliance with Turkish Commercial Code, Capital Markets Law and the Decree in the force of Law numbered 660 and principles determined pursuant to the secondary legislation that is effective in this scope, PwC Bağımsız Denetim ve Serbest Muhasebeci Mali Müşavirlik Anonim Şirketi (PricewaterhouseCoopers) be appointed as the independent audit institution with a view to subjecting financial reports of our company in the fiscal period of 01 January 2023 - 31 March 2023 to independent auditing and performing other relevant operations.
Click here to reach the annual reports of EIS.
Click here to see Rules of Conduct of EIS.
Click here for contact information of EİS Investor Relations Department.
Click here to learn about more about Eczacıbaşı group.
